Skip to main content

Scientific Contributions

5P30AG072931

Michigan Alzheimer’s Disease Research Core 

Name of PD/PI: Paulson

Primary Place of Performance: University of Michigan/Michigan State University/Wayne State University

 

P30AG053760-03S01

Michigan Alzheimer’s Disease Research Core-Supplement

Name of PD/PI: Paulson (Lead: Vega)

Primary Place of Performance: University of Michigan/Michigan State University

R01AG070951

Brain Health and Ethnic Disparities in ADRD Risk: The Case of Arab Americans

Name of PD/PI: Antonucci/Zahodne/Ajrouch

Primary Place of Performance: University of Michigan/Michigan State University

 

R01AG063979

Tau-Mediated Regulation and Dysregulation of Protein Phosphatase 1

Name of PD/PI: Kanaan

Primary Place of Performance: Michigan State University

 

R01AG087121-01A1

ADRD risk and resilience among Black Americans a 20-year longitudinal study

Name of PD/PI: Mezuk

Primary Place of Performance: University of Michigan

 

DoD Application

Integrating Behavioral and Biomarker Measures to Understand Accelerated Aging in Multiple Sclerosis

Name of PD/PI: Monaghan

Primary Place of Performance: University of Michigan

 

Tetrad Program

Establishing a novel zebrafish model for Alzheimer’s disease drug discovery

Name of PD/PI: Chung-Davidson/Kuo/Lamp

Primary Place of Performance: Michigan State University

 

The Campbell Foundation

Phosphorylation of a Basic Helix Loop Helix Protein as a Mechanism to Control Dopaminergic Gene Expression

Name of PD/PI: DeLano-Taylor

Primary Place of Performance: Grand Valley State University

Cornett EM, Dickson BM, Krajewski K, Spellmon N, Umstead A, Vaughan RM, Shaw KM, Versluis PP, Cowles MW, Brunzelle J, Yang Z, Vega IE, Sun ZW, Rothbart SB.  (2018) A functional proteomics platform to reveal the sequence determinants of lysine methyltransferase substrate selectivity. Science Advances 4(11):eaav2623 (PMID: 30275048) 

Umstead A, Soliman AS, Lamp J, Vega IE (2020) Validation of recombinant human protein purified from bacteria: An important step to increase scientific rigor. Anal Biochem. 611:113999. (PMID: 33098768) 

Li P, Ensink E, Lang S, Marshall L, Schilthuis M, Lamp J, Vega I, Labrie V (2020) Hemispheric asymmetry in the human brain and in Parkinson’s disease is linked to divergent epigenetic patterns in neurons. Genome Biology 21(1):61. (PMID: 32151270) 

Li P, Killinger BA, Ensink E, Beddows I, Yilmaz A, Lubben N, Lamp J, Schilthuis M, Vega IE, Woltjer R, Pospisilik JA, Brundin P, Brundin L, Graham SF, Labrie V. (2021) Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease. Metabolites. 11(1):29. (PMID: 33406628) 

Gordevicius J, Li P, Marshall L, Killinger B, Lang S, Ensink E, Kuhn N, Cui W, Maroof N, Lauria R, Rueb C, Seibourg-Polster J, Maliver P, Lamp J, Vega I, Manfredsson F, Britschgi M, Labrie V (2021) Epigenetic inactivation of the autophagy–lysosomal system in appendix in Parkinson’s disease. Nat Comms 12(1):5134. (PMID: 34446734) 

Soliman AS, Umstead A, Grabinski T, Kanaan NM, Lee A, Ryan J, Lamp JVega IE. (2021) EFhd2 brain interactome reveals its association with different cellular and molecular processes. J Neurochem. 159(6):992-1007 (PMID: 34543436) 

Yan Y, Mukherjee S, Harikumar KG, Strutzenberg TS, Zhou XE, Powell KS, Xu TH, Sheldon RD, Lamp J, Brunzelle JS, Radziwon K, Ellis A, Novick SJ, Vega IE, Jones RG, Miller LJ, Xu HE, Griffin PR, Kossiakoff AA, Melcher K (2021) Structure of an AMPK complex in its inactive, ATP-bound state. Science 373(6553): 413-419. (PMID: 34437114) 

Zhou XE, Suino-Powell K, Schultz CR, Aleiwi B, Brunzelle JS, Lamp JVega IE, Ellsworth E, Bachmann AS, Melcher K. (2021) Structural basis of binding and inhibition of ornithine decarboxylase by 1-amino-oxy-3-aminopropane. Biochem J.478(23):4137-4149. (PMID: 34796899) 

Patterson JR, Hirst WD, Howe JW, Russell CP, Cole-Strauss A, Kemp CJ, Duffy MF, Lamp J, Umstead A, Kubik M, Stoll AC, Vega IE, Steece-Collier K, Chen Y, Campbell AC, Nezich CL, Glajch KE, Sortwell CE. (2022) Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein. NPJ Parkinsons Dis. 8(1):61. (PMID: 35610264) 

Zhou XE, Schultz CR, Suino Powell K, Henrickson A, Lamp J, Brunzelle JS, Demeler B, Vega IE, Bachmann AS, Melcher K. (2022) Structure and Enzymatic Activity of an Intellectual Disability-Associated Ornithine Decarboxylase Variant, G84R. ACS Omega. 7(38):34665-34675. 

Soliman AS, Umstead A, Lamp J, Vega IE. (2024) EFhd2 co-aggregates with monomeric and filamentous tau in vitro. Front Neurosci. 18:1373410. (PMID: 38765673). 

Alhadidy M, Mueller R, Lamp J, Kanaan N. (2025). Polyamination with spermidine enhances pathogenic tau conformations while reducing filamentous aggregate formation in vitro. 482(12):877-899. (PMID: 40401986). 

Gandu S, Rodriguez A, Lamp J, Patel M, Madura K, Vega IE, Firestein B (2025) Cypin regulates proteasome-independent K63-linked polyubiquitination to shape synaptic content. Sci. Adv. 11(28):eads5467. (PMID: 40644549). 

Atwa A, Alhadidy M, Lamp J, Combs B, Kanaan N. (2025). BioID2-Based Tau Interactome Reveals Novel and Known Protein Interactions Associated with Multiple Cellular Pathways. Journal of Proteome Research. 24(10):5099-5115. (PMID: 40910579).

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF ENDOMETRIOSIS AND ENDOMETRIOSIS-RELATED DISORDERS

US Patent No. 16/929,403

Publication Date: February 18, 2021

 

BUCCAL SWAB-BASED BIOMARKERS FOR SCHIZOPHRENIA

Provisional application filed. Patent pending. ID:2025-015

https://techfinder.rutgers.edu/tech/Buccal_swab-based_biomarkers_for_schizophrenia

Publication Date: April 30, 2025